Collaborative and Other Relationships (Tables)

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Co-promotion profit sharing formula

As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:

After LUNSUMIO Approval until the First Threshold Date	37.5	%
After First Threshold Date until the Second Threshold Date	35.0	%
After Second Threshold Date	30.0	%

Pretax profit sharing formula

Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:

Until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

Revenues from anti-CD20 therapeutic programs

Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.

	For the Three Months Ended March 31,
(In millions)	2023		2022
Royalty revenue on sales of OCREVUS	$	283.6	$	252.3
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO	112.5		143.2
Other revenue from anti-CD20 therapeutic programs	3.4		3.9
Total revenue from anti-CD20 therapeutic programs	$	399.5	$	399.4

Summary of activity related to Aducanumab collaboration

A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:

	For the Three Months Ended March 31,
(In millions)		2022
Total ADUHELM Collaboration development expense		$	44.2
Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income		24.3
Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement		95.0
Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income		50.9

Summary of activity related to the UCB collaboration

A summary of development expense related to the UCB collaboration agreement is as follows:

	For the Three Months Ended March 31,
(In millions)	2023		2022
Total UCB collaboration development expense	$	18.3	$	17.6
Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	9.2		8.8

Summary of Activity Related to Denali Therapeutics Collaboration

A summary of development expense related to this collaboration is as follows:

	For the Three Months Ended March 31,
(In millions)	2023		2022
Total Denali collaboration development expense	$	16.6	$	14.9
Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	10.0		8.9

Summary of Activity Related to BAN2401 and Elenbecestat Collaboration

	For the Three Months Ended March 31,
(In millions)	2023		2022
Total development expense incurred by the collaboration related to the advancement of LEQEMBI	$	107.9	$	77.0
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	54.0		38.5
Total sales and marketing expense incurred by the LEQEMBI Collaboration(1)	10.5		15.9
Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income(1)	5.3		8.0

(1) Beginning in the first quarter of 2023 reimbursement to Eisai for our share of U.S. LEQEMBI selling, general and administrative expense is recognized in revenue from LEQEMBI Collaboration within our condensed consolidated statements of income.

Summary of Activity Related to Sangamo Therapeutics

A summary of development expense related to this collaboration is as follows:

	For the Three Months Ended March 31,
(In millions)	2023		2022
Total Sangamo collaboration development expense	$	5.1	$	8.3
Biogen's share of Sangamo collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	2.3		5.5

Summary of Activity Related to Sage Therapeutics

A summary of development and sales and marketing expense related to this collaboration is as follows:

	For the Three Months Ended March 31,
(In millions)	2023		2022
Total Sage collaboration development expense	$	34.8	$	38.7
Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	17.4		19.4
Total Sage sales and marketing expense incurred by the collaboration	38.2		18.4
Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income	19.1		9.2